Hyaluronic acid 35 normalizes TLR4 signaling in Kupffer cells from ethanol-fed rats via regulation of microRNA291b and its target Tollip

Paramananda Saikia1,3, Sanjoy Roychowdhury2,3, Damien Bellos1,3, Katherine A. Pollard1, Megan R. McMullen1, Rebecca L. McCullough1, Arthur J. McCullough1,2, Pierre Gholam4, Carol de la Motte1,3 & Laura E. Nagy1,2,3

TLR4 signaling in hepatic macrophages is increased after chronic ethanol feeding. Treatment of hepatic macrophages after chronic ethanol feeding with small-specific sized hyaluronic acid 35 (HA35) normalizes TLR4 signaling; however, the mechanisms for HA35 action are not completely understood. Here we used Next Generation Sequencing of microRNAs to identify negative regulators of TLR4 signaling reciprocally modulated by ethanol and HA35 in hepatic macrophages. Eleven microRNAs were up-regulated by ethanol; only 4 microRNAs, including miR291b, were decreased by HA35. Bioinformatics analysis identified Tollip, a negative regulator of TLR4, as a target of miR291b. Tollip expression was decreased in hepatic macrophages from ethanol-fed rats, but treatment with HA35 or transfection with a miR291b hairpin inhibitor restored Tollip expression and normalized TLR4-stimulated TNFα expression. In peripheral blood monocytes isolated from patients with alcoholic hepatitis, expression of TNFα mRNA was robustly increased in response to challenge with lipopolysaccharide. Importantly, pre-treatment with HA35 reduced TNFα expression by more than 50%. Taken together, we have identified miR291b as a critical miRNA up-regulated by ethanol. Normalization of the miR291b → Tollip pathway by HA35 ameliorated ethanol-induced sensitization of TLR4 signaling in macrophages/monocytes, suggesting that HA35 may be a novel therapeutic agent in the treatment of ALD.

Alcoholic liver disease (ALD) develops in approximately 20% of all alcoholics with a higher prevalence in females1. The development of fibrosis and cirrhosis is a complex process involving both parenchymal and non-parenchymal cells resident in the liver, as well as the recruitment of other cell types to the liver in response to damage and inflammation1. There is a growing appreciation that inter-organ cross talk between the intestine and liver drives the progression of ethanol-induced liver injury. Impairment of intestinal barrier function is associated with the progression of ethanol-induced liver injury in both humans after heavy alcohol consumption and in rodent models of chronic ethanol exposure2. Increased exposure of Kupffer cells, the resident hepatic macrophages, to gut-derived LPS during chronic ethanol, activates TLR4-dependent production of inflammatory mediators4. In addition to causing increased contact with LPS, we and others have shown that chronic ethanol exposure also sensitizes Kupffer cells to LPS, resulting in increased production of inflammatory mediators4. Further, dysregulation of the microbiome during chronic ethanol exposure likely contributes to the development of liver disease5. Despite this understanding of the progression of ALD, effective prevention and treatment strategies have remained elusive.

Hyaluronan (HA), a large linear glycan, is an abundant extracellular matrix component and is produced as a straight chain polymer strictly composed of repeating disaccharides of D-glucuronic acid and
N-acetylglucosamine. HA is produced at cell surfaces by one or more plasma membrane hyaluronan synthases (HAS1, HAS2 and HAS3)\(^6\). High molecular weight matrix hyaluronan can be degraded in response to injury\(^7\). The resulting HA fragments can have either pro-inflammatory or protective, anti-inflammatory effects, depending on the size and molecular structure of the HA fragments, as well as the cellular and tissue environment\(^7\).

Recently, a small specific-sized hyaluronic acid with an average molecular weight of 35kD (HA35) was identified as a potential therapeutic agent for ALD\(^8\). HA35 normalized TLR4-stimulated cytokine production in Kupffer cells and protected mice from short-term ethanol-induced gut and liver injury\(^8\). In order to understand the mechanisms for the anti-inflammatory effects of HA35 on Kupffer cells after chronic ethanol feeding, an unbiased Next Generation Sequencing analysis of miRNAs was performed. Focusing on miRNAs whose expression is decreased by ethanol revealed that chronic ethanol enhanced a miR181b-3p\(\rightarrow\)importin\(\alpha\)5 regulatory axis in hepatic macrophages that contributed to the sensitization of TLR4-dependent cytokine expression in these Kupffer cells. Treatment with HA35 normalized this pathway and reduced inflammatory activity\(^8\).

In this investigation, we have taken the complementary approach to understanding the anti-inflammatory mechanisms for HA35 action in Kupffer cells after chronic ethanol exposure and analyzed miRNAs whose expression was increased in Kupffer cells after chronic ethanol feeding and in turn restored by \textit{ex vivo} treatment of HA35.

Figure 1. HA35 decreased LPS and PamCys3K-stimulated TNF\(\alpha\) mRNA expression in primary cultures of rat Kupffer cells from ethanol and pair-fed rats, as well as PBMCs from patients with alcoholic hepatitis. Wistar rats were allowed free access to a Lieber-DeCarli ethanol diet or pair-fed control diet for 4 weeks. Kupffer cells were isolated and cultured overnight. Kupffer cells were then treated with 100\(\mu\)g/ml HA35 for 5h and then challenged with (A) 10 ng/ml LPS or (B) 10 ng/ml PamCys3K (PAM3) for an additional 1hr. Expression of TNF\(\alpha\) mRNA was measured by qRT-PCR and normalized to 18S rRNA. (C) PBMCs isolated from patients with AH and healthy controls, cultured overnight and then treated or not with 100\(\mu\)g/ml HA35. PBMCs were then challenged with 10 ng/ml LPS for an additional 1hr. Expression of TNF\(\alpha\) mRNA was measured by qRT-PCR and normalized to 18S rRNA. (A/B) \(n=4\); (C) \(n=10\) for AH and 6 for healthy controls. Values represent means \(\pm\) SEM. Values with different alphabetical superscripts are significantly different from each other, \(p<0.05\).

| Characteristics | Alcoholic hepatitis patients | Healthy controls |
|-----------------|-----------------------------|-----------------|
| Age (years)     | Median (25–75 IQR)          | Median (25–75 IQR) |
| Male n (%)      | 47(26–60)                   | 27(23–48)       |
| Alcohol Consumption (g/day) | 60(37–100) | 50(12.5–50) |

Table 1. Clinical characteristics of alcoholic hepatitis patients and healthy controls. Values are median and intraquartile range, \(n=10\) for alcoholic hepatitis and \(n=6\) for healthy controls.
expression via a CD44-dependent mechanism. Importantly, Tollip, a negative regulator of TLR4-MyD88-IRAK signaling, was identified as a target of miR291b. Tollip is known to be post-transcriptionally regulated by other miRNAs, including miR-31. Tollip suppresses the sensitivity of macrophages to stimulation by LPS, as well as IL-1, although this response may vary with dose of LPS. Tollip expression was decreased in Kupffer cells after chronic ethanol, but restored by HA35; restoration of Tollip expression contributed to the normalization of TLR4 signaling in Kupffer cells after chronic ethanol feeding.

Results

HA35 decreased LPS and PamCys3K-stimulated TNFα mRNA expression in primary cultures of Kupffer cells from ethanol and pair-fed rats, as well as in PBMCs from patients with alcoholic hepatitis. Kupffer cell activation is an early event during progression of ALD and chronic ethanol exposure sensitizes Kupffer cells to TLR4-dependent cytokine production. Understanding the molecular mechanisms for this sensitization and identification of anti-inflammatory agents that can restore normal responses is a clinically relevant area of investigation. We have recently discovered that small-specific-sized HA35 can normalize TLR4-mediated cytokine expression by rat Kupffer cells after chronic ethanol exposure6. Chronic ethanol also sensitized Kupffer cells to stimulation by PamCys3K, a TLR2 ligand, when compared to the response of Kupffer cells isolated from pair-fed control rats (Fig. 1B). Pre-treatment with HA35 also normalized the sensitivity of Kupffer cells from ethanol-fed rats to stimulation by PamCys3K, without affecting the sensitivity of cells from pair-fed controls (Fig. 1B).

In order to determine whether HA35 regulates TLR4-dependent cytokine expression in patients with alcoholic hepatitis (AH), we studied isolated peripheral blood monocytes (PBMCs) from a cohort of patients with moderate to severe AH, with Model for End Stage Liver Disease (MELD) scores ranging from 17–33, as well as a cohort of healthy control subjects. Table 1 provides information on the clinical characteristics of the AH patients. PBMCs isolated from patients with AH or healthy controls were cultured with or without HA35 for 5h and then challenged with LPS (Fig. 1C). LPS increased the expression of TNFα mRNA in PBMCs from both controls and patients with AH; the LPS-stimulated response was greater in patients with AH compared to controls, as has been previously reported. LPS-stimulated expression of TNFα mRNA was reduced in PBMCs from both patients with AH and healthy controls that were pre-treated with HA35 (Fig. 1C).

siRNA knock-down of receptors for HA in Kupffer cells from ethanol-fed rats demonstrated the importance of CD44 in normalizing TLR4-dependent TNFα expression. HA binds to different cell surface receptors to initiate cell signaling. CD44, TLR4, TLR2, and RHAMM are known to interact with HA; ligation of these receptors by HA depends both on the size of the HA molecule and the specific cell type. In order to identify the key receptor(s) mediating the protective effect of HA35 in Kupffer cells, expression of each of these four receptors was knocked-down by nucleofection of siRNA targeted to each receptor. Comparison in the expression of TLR4 (Fig. 2A), TLR2 (Fig. 2B), RHAMM (Fig. 2C) and CD44 (Fig. 2D) between cells transfected with scrambled versus targeted siRNA confirmed effective knock-down of each of these receptors.

When TLR4 was knocked-down in primary cultures of Kupffer cells with targeted siRNA, LPS stimulation of TNFα expression was very low, as would be expected (Supplemental Fig. 1). Therefore, in order to ascertain the contribution of TLR4 to the HA-mediated normalization of Kupffer cell cytokine expression, after knock-down of TLR4, Kupffer cells were challenged with the TLR2 ligand PamCys3K (Fig. 3A). Challenge with PamCys3K increased expression of TNFα in Kupffer cells nucleofected with either scrambled siRNA or siRNA targeted to knock-down TLR4 (Fig. 3A). However, even when TLR4 was knocked-down, pre-treatment with HA35 still reduced PamCys3K-stimulated expression of TNFα mRNA (Fig. 3A). Similarly, when Kupffer cells were nucleofected with siRNA targeting TLR2 and RHAMM, HA35 pre-treatment was still reduced LPS-stimulated TNFα expression (Fig. 3B/C). Only when the expression of CD44 was knocked-down was the protective effect of HA35 on LPS-stimulated TNFα expression ameliorated (Fig. 3D). Taken together, these data indicate that CD44 mediates the effects of HA35 on Kupffer cells from ethanol-fed rats.

Identification of multiple miRNAs up-regulated by ethanol and down-regulated by HA35 in Kupffer cells by Next Generation Sequencing. miRNAs, non-protein coding RNAs of 20–22 nucleotides, are key regulators of inflammatory responses in innate immune cells, providing both positive and negative regulation of TLR4 signaling. Therefore, we hypothesized the regulation of miRNA expression in Kupffer cells contributed to their response to ethanol and HA35. To test this hypothesis, Next Generation Sequencing (NGS) of miRNAs isolated from Kupffer cells from pair- and ethanol-fed rats after treatment with or without HA35 for 5h was conducted on the Illumina platform. Ethanol feeding up-regulated 11 miRNAs by more than two-fold (Fig. 4A). Of these miRNAs, HA35 treatment normalized the expression of only 4 miRNAs, including miR291b (Fig. 4B). Using the miRDB (www.mirdb.org) analysis tool, ~350 miR291b-targeted genes were retrieved with a target prediction score greater than 60; predicted target scores greater than 60 indicate a high likelihood of miRNA binding to a particular target (Supplemental Table 1). Tollip, a negative regulator of the MyD88-dependent pathway of TLR2 and TLR4 signaling, was identified to have a binding site in its 3′UTR that recognizes miR291b with a target prediction score of 79 in both rat and mouse. Further, miR291b was ranked at 15 from 45 miRNAs predicted to bind to Tollip in rat and 11 from 92 miRNAs predicted to bind Tollip in mouse. Target Scan (www.targetscan.org), another bioinformatics tool, also confirmed Tollip as a potential target of miR291b. Based on these in silico analyses, we predicted that increased expression of miR291b in response to ethanol feeding would decrease the expression of Tollip protein. If miR291b regulates the expression of Tollip, we hypothesized that it could be a critical mediator of both the sensitization of Kupffer cells from ethanol-fed rats to TLR2/TLR4 signaling, as well as the protective effects of HA35.
The reciprocal regulation of miR291b by ethanol and HA35 was confirmed by real-time PCR (Fig. 4D). Expression of miR291b was not sensitive to pre-treatment with HA7, a small-specific sized HA fragment that does not normalize TLR4 signaling in Kupffer cells from ethanol-fed rats (Fig. 4D). In order to confirm a role for CD44 in mediating the impact of HA35 on expression of miR291b, Kupffer cells were nucleofected with scrambled siRNA or siRNA targeting CD44. Similar to non-transfected cells, when cells were nucleofected with scrambled siRNA, miR291b expression was increased in Kupffer cells from ethanol-fed rats and normalized by treatment with HA35 (Fig. 4E). However, when CD44 was knocked-down in Kupffer cells, expression of miR291b was not decreased by HA35 treatment (Fig. 4E).

We have recently reported that treatment of mice with HA35 by gavage protects mice from short-term ethanol-induced liver and gut injury. Here we investigated whether short-term ethanol feeding and/or oral provision of HA35 affected the expression of hepatic miR291b. Short-term ethanol feeding increased expression of miR291b in liver; both hepatocytes and non-parenchymal cells exhibited expression as assessed via in situ hybridization (Fig. 4F). Treatment of mice with HA35 during ethanol feeding decreased expression of miR291b in both cell types (Fig. 4F).
Expression of Tollip protein was lower in Kupffer cells from ethanol-fed rats and increased by HA35 or the presence of a miR291b hairpin inhibitor. If increased expression of miR291b modulated Tollip expression, then we would expect to see less Tollip protein in Kupffer cells from ethanol-fed rats. Western blot analysis revealed that Tollip expression was lower in Kupffer cells from ethanol-fed rats; pre-treatment with HA35 normalized expression in Kupffer cells from ethanol-fed rats, but did not impact Tollip expression in Kupffer cells from pair-fed rats (Fig. 5A). Challenge with LPS for 60 min had no effect on Tollip protein quantity (Fig. 5A). If the HA35-mediated reduction in miR291b expression mediated the ethanol-induced increase in the quantity of Tollip protein, then transfection of a miR291b hairpin inhibitor should normalize Tollip protein, as well as TLR4 signaling, in Kupffer cells from ethanol-fed rats. Transfection with a miR291b hairpin inhibitor, but not with a control hairpin, increased Tollip protein expression (Fig. 5B) and normalized LPS-stimulated expression of TNFα mRNA (Fig. 5C).

Discussion
Understanding the mechanisms by which chronic ethanol sensitizes macrophages to TLR-dependent activation is critical to the development of effective therapeutics for treatment of alcoholic liver disease. An expanding number of miRNAs have been identified to regulate expression of the TLR2/4 signaling machinery, as well as the transcription factors and cytokines induced by TLR2/4 signaling21. Only a few examples of the impact of chronic ethanol on miRNA controlling TLR-mediated responses have been reported. For example, miR155 expression is up-regulated in Kupffer cells and contributes to ethanol-induced stabilization of TNFα mRNA23. Chronic ethanol feeding decreases the expression of miRNA181b-3p, which in turn upregulates the expression of the nuclear-cytoplasmic shuttling protein, importin α5, contributing to increased p65 translocation to the nucleus in Kupffer cells after chronic ethanol feeding4. Here we have identified miR291b as an additional miR up-regulated by chronic ethanol that contributes to sensitization of TLR2/4 signaling by decreasing the expression of Tollip, a negative regulator of MyD88-dependent signaling (Fig. 6). Expression of miR291b and Tollip, as well as TLR2/4-stimulated TNFα expression can be normalized by treatment of Kupffer cells with HA35. Importantly, treatment of PBMCs isolated from patients with AH with HA35 also potently reduced the sensitivity of TLR4-mediated cytokine expression.
Figure 4. Next Generation Sequencing of miRNAs in Kupffer cells from ethanol- and pair-fed rats after treatment with or without HA35. (A–D) Wistar rats were allowed free access to a Lieber-DeCarli ethanol diet or pair-fed control diet for 4 weeks. Kupffer cells were isolated and cultured overnight. Kupffer cells were then treated with or without 100 μg/ml HA35 for 5 h. Total miRNAs were isolated and analyzed by NGS. (A) Heat maps illustrate the changes in expression for the 11 miRNAs identified whose expression was increased by more than 2-fold by ethanol feeding. (B) Of these eleven miRNA, heat maps are shown for the 4 miRNAs whose expression was decreased by treatment with HA35. Fold changes are shown in the column to the left of the heat maps. (C) Predicted binding site for miR291b in the 3′ UTR of Tollip (mirDB). Sequence alignment between miR291b and Tollip is illustrated. (D) Kupffer cells isolated from ethanol- and pair-fed rats were treated or not with HA35 or HA7 for 5 h and expression of miR291b measured by qRT-PCR and normalized to Hs-SNORD68-11. (E) Isolated Kupffer cells were nucleofected with scrambled siRNA or siRNA targeted against CD44. 18 h post-nucleofection, Kupffer cells were treated or not with 100 μg/ml HA35 for 5 h and expression of miR291b measured by qRT-PCR and normalized to Hs-SNORD68-11. (F) C57BL/6J mice were allowed free access to an ethanol containing diet for 4 days (2 days at 1% (v/v) ethanol, followed by 2 days 6% (v/v) ethanol).
or pair-fed an isocaloric control diet. Mice were gavaged once daily for the last 3 days of ethanol feeding with HA35 at 15 mg/kg body weight or saline as a vehicle control the last three days of the study. Paraffin-embedded livers were de-paraffinized followed by in situ hybridization for miR291b using locked nucleic acid probes tagged with digoxigenin at both the 5’ and 3’ ends. All images were captured using 40X objectives. miR291b–positive cells were counted using Image Pro-Plus software and analyzed. Zoomed images illustrate positive staining in cells identified by morphology as hepatocytes (pink) and non-parenchymal cells (white). (A, B) n = 3 (C) n = 5 (D) n = 4 (E) n = 3–6. (C, D, E) Values represent means ± SEM. Values with different alphabetical superscripts are significantly different from each other, p < 0.05.

The intracellular signaling pathways activated by TLRs are mediated through the adaptor molecules MyD88 and TRIF, ultimately leading to the induction of an inflammatory response. Given the critical importance of TLR signaling in inflammation, it is not surprising that multiple negative regulators contribute to the modulation of the inflammatory response by dampening TLR signals. Important negative regulators include Tollip, as well as suppressor of cytokine signaling 1 (SOCS-1) and interleukin 1 receptor-associated kinase (IRAK)-M. Tollip protein functions as a negative regulator of the TLR4 signaling pathway through its interaction with IRAK. Tollip binds to IRAK-1 and halts signaling by blocking recruitment of IRAK-4 to the myddosome, thereby, preventing the phosphorylation and activation of IRAK-1. Interestingly, Kupffer cells have a higher expression of Tollip mRNA compared to peripheral monocytes, likely contributing to their relatively tolerogenic status in the liver. Here we find that chronic ethanol feeding decreases the expression of Tollip protein in Kupffer cells, consistent with the increased sensitivity of TLR2 and TLR4 signaling after chronic ethanol (Fig. 1). Tollip expression can be regulated at the transcriptional, as well as post-transcriptional level. The 3’UTR of Tollip contains a miR31 binding site; miR31 binding inhibits translation. Here, using TargetScan, we identified a miR291b binding site in the Tollip 3’UTR that was associated with decreased Tollip protein quantity in Kupffer cells. Importantly, treatment of Kupffer cells from ethanol-fed rats with either HA35 or a miR291b inhibitor restored Tollip expression and normalized TLR4 sensitivity (Fig. 5). Taken together, these data indicate that extent of Tollip expression in Kupffer cells likely plays an important role as a rheostat of TLR2/4 signaling in the liver.

Expression of miR291b was also found to be increased in the liver of mice in response to short-term ethanol feeding (Fig. 4). Interestingly, miR291b was detected in both non-parenchymal cells and hepatocytes; treatment of mice with HA35 prevented these ethanol-induced increases in both cell types. While the increase in miR291b expression in non-parenchymal cells is consistent with our data from Kupffer cells following chronic ethanol feeding, induction of miR291b in hepatocytes may also be of pathophysiological significance, as miR291b-3p has been reported to induce hepatocyte apoptosis by downregulating HuR and Bcl-2 expression and also impact glucose induction of miR291b in hepatocytes may also be of pathophysiological significance, as miR291b-3p has been reported to induce hepatocyte apoptosis by downregulating HuR and Bcl-2 expression and also impact glucose metabolism in hepatocytes. Therefore, future investigations will investigate if expression of miR291b in hepatocytes response to ethanol exposure might play an important role in ethanol-induced hepatocyte injury.

HA, a major glycosaminoglycan in the extracellular matrix, is recognized as an important danger-associated molecular pattern (DAMP) that regulates innate immunity. Despite the potent ability of HA to stimulate inflammatory responses, specific-sized HA fragments can also have protective, anti-inflammatory effects. Purified milk HA increases expression of the broad spectrum antimicrobial peptide, human β-defensin 2 (HBD2) and protects from Salmonella infection in human epithelium in vitro. Highly purified HA35 specifically mimics the effects of milk HA, increasing expression of HBD2 and protecting epithelium from Salmonella. HA35 also protects mice from in vivo infection with Citrobacter rodentium (a model for human enteropathogenic E. coli infection) and modulates epithelial ZO1 expression in vivo in multiple models of colitis. HA is being developed as a novel dietary supplement for formula-fed infants and children at risk for enteric bacterial infection, as well as patients who suffer from bacterial dysbiosis, e.g. individuals with inflammatory bowel disease (IBD). Our recent data indicate that HA35 can also protect mice from gut and liver injury in response to short-term ethanol feeding.

The concentration of endogenous HA35 in healthy individuals and patients with liver disease is not known. However, it is unlikely that there is a sufficient concentration of endogenous HA35 to mimic the results of our pharmacological interventions with purified HA35. For example, it is estimated that the total hyaluronan content in a 70 kg human is 15 g. The dose of HA35 provided therapeutically to mice in our study was 1.5 g/kg or the equivalent of 105 g in a 70 kg human. Further, total concentrations of all sizes of hyaluronan circulating in the serum, measured by ELISA, are on the order of 10–100 micrograms/L in healthy individuals and about ~50 micrograms/L in rats. In different stages of alcoholic liver disease, total concentration of all sizes of hyaluronan circulating increases with severity of inflammation and fibrosis to concentrations ranging from 500–1000 micrograms/L. Total HA is more predictive of stage of fibrosis, rather than severity of inflammation. Viewed from the perspective of the circulating concentrations of all sizes of hyaluronan both in health and liver disease, it is unlikely that concentrations of endogenous specific-sized HA35 would likely have an impact on TLR4 signaling, as purified HA35 was used at a pharmacological concentration of 100 grams/L (100 micrograms/ml) in our cell-based studies.

HA communicates with many cell types in a size-specific manner, using at least four signaling receptors including: (1) CD44, a ubiquitously-expressed cell surface protein that recognizes HA sizes greater than 8 sugar moieties in length; (2) RHAMM (receptor for HA mediated motility) which is important in signaling cell migration; (3) toll-like receptor (TLR) pattern recognition molecules TLR4 and TLR2; (4) CD44, as the critical receptor for HA35-mediated anti-inflammatory effects in Kupffer cells after chronic ethanol feeding (Fig. 3). The interaction of hyaluronan with CD44 is dependent on both the size of the HA and cellular variant of CD44; depending on the context HA ligation of CD44 can be either pro- or anti-inflammatory.
Interestingly, CD44 can also interact with other ligands, including osteopontin. Under some conditions, osteopontin, like HA35, can protect mice from ethanol-induced liver injury.

In summary, here we have identified a miR291b-mediated down-regulation of Tollip expression in Kupffer cells from ethanol-fed rats that contributes to the sensitization of TLR2/4 signaling after chronic ethanol (Fig. 6). Importantly, this dysregulation of TLR2/4 signaling was normalized by the treatment of Kupffer cells or PBMCs from patients with alcoholic hepatitis with HA35. These data add to a growing number of miRNAs involved in the response to macrophages to ethanol, including miR15523 and miR181b-3p. Through normalization of expression miR291b, as well as miR181b-3p, treatment of HA35 protected from the effects of ethanol in Kupffer cells and PBMCs from patients with AH, suggesting that HA35 has potential as a therapeutic agent for the treatment of ALD.

Materials and Methods

Chronic ethanol feeding to rats. All procedures involving animals were approved by and carried out according to the guidelines of the Institutional Animal Care and Use Committee at the Cleveland Clinic. Adult male Wistar rats weighing 140–150 g were purchased from Envigo (Indianapolis, IN). Chronic ethanol feeding to rats and the isolation and culture of Kupffer cells were performed as previously described. Briefly, rats were weight matched and then randomly assigned to pair-fed or ethanol-fed groups. Rats were allowed free access to the Lieber-DeCarli high-fat liquid diet (#710260, Dyets, Bethlehem, PA) for 2 days. Ethanol-fed rats were allowed free access to a liquid diet containing 17% of the calories (3.3% vol/vol) from ethanol for 2 days and then a liquid diet containing 35% of the calories (6.7% vol/vol) from ethanol for 4 weeks. Control rats were pair-fed a liquid diet in which maltose dextrin was substituted isocalorically for ethanol over the entire feeding period.

Isolation and culture of Kupffer cells. Kupffer cells were isolated and cultured, as previously described. After 18 hours in culture, cells were treated with or without 100 μg/ml small-specific-sized HA of average molecular weight of 7kD (HA35) or 35kD (HA35) (Lifecore Biomedical, LLC, Chaska, MN) for 5 h. Kupffer cells were then challenged with 10 ng/ml LPS (Escherichia Coli strain 0111:B4, Sigma-Aldrich) or PamCys3K, as indicated in the figure legends. For experiments using miRNA hairpin inhibitor or siRNA, Kupffer cells were nucleofected using the Amaxa mouse macrophage Nucleofector kit using the Y-001 program (Lonza, Cologne, Germany), as previously reported. After nucleofection, cells retained sensitivity to LPS, ethanol and HA35; however, the extent of expression of TNFα was lower than in non-transfected cells (data not shown). Validated ON TARGET plus specific siRNAs SMART pool (rat CD44, cat no. L-089166-02-0005; rat TLR4, cat no. L-09819-02-0005; rat RHAMM, cat no. L-089927-02-0005 and rat TLR2, cat no. L-092211-02-0005) were purchased from Dharmacon, GE. Sequences of miRNAs primers and hairpin inhibitor are listed in Supplemental Table 2.
Short-term ethanol feeding to mice. Ten to twelve week old female C57BL6/J mice were purchased from Jackson Laboratories (Bar Harbor, ME) and allowed free access to a Lieber-DeCarli liquid diet containing ethanol or a pair-fed control diet that isocalorically substituted maltose dextrin for ethanol. Mice were housed two per micro-isolator cage and were maintained in a temperature regulated facility with a 12 hour light-dark cycle, with Nylabones provided for environmental enrichment. Mice were weight matched and randomly distributed to ethanol or control diets. They were then introduced to the control liquid diet for two days. Ethanol diets were initiated at 1% (v/v) for two days and then increased to 6% (v/v) or 32% of total calories for an additional two days. During the last three days of feeding, mice were gavaged with 15 mg/kg HA35 in sterile saline or an equivalent volume of saline (vehicle) at 1:30 pm. The morning after the last HA35 treatment, ethanol- and pair-fed mice were anesthetized and samples collected prior to euthanasia. The livers were perfused, excised and sectioned for FISH analysis.

Human subjects. Patients with a confirmed diagnosis of alcoholic hepatitis were enrolled. The diagnosis of alcoholic hepatitis was performed by clinicians at the Cleveland Clinic and University Hospitals, Cleveland based on the patients’ medical history, physical examination, and laboratory data and according to the guidelines of the American College of Gastroenterology [https://gi.org/clinical-guidelines/]. Healthy control subjects were recruited from the Clinical Research Unit at the Cleveland Clinic. The study protocol was approved by the Institutional Review Board for the Protection of Human Subjects in Research at the Cleveland Clinic and University Hospitals, Cleveland. All methods were performed in accordance with the IRB’s guidelines and regulations and written informed consent was obtained from all subjects.

Isolation and stimulation of human peripheral blood mononuclear cells (PBMCs). Isolation of PBMCs from human blood was performed by density gradient centrifugation on Ficoll-Paque PLUS. Briefly, 1 mL of freshly collected Buffy Coat was mixed at a ratio of 1:1 (vol/vol) with PBS at room temperature and 2 mL of the mixture was layered to 10 mL Ficoll-Paque PLUS in 15 mL tubes. After centrifugation at 800 g for 30 min at 20 °C (no brake),uffy coat fractions were collected, pooled, resuspended in PBS and centrifuged at 800 g for 20 min at 20 °C. The pellets were resuspended in 10 mL of PBS and again centrifuged at 800 g for 20 min at 20 °C, the top 10 mL of platelet-rich solution was discarded and the rest was centrifuged at 800 g for 5 min at 20 °C. The harvested PBMCs were counted and cultured in RPMI-1640 supplemented with 0.02 M HEPES, 100 μM Penicillin-streptomycin and 10% heat-inactivated FBS in 96-well plates in humidified atmosphere (5% CO₂, 37 °C). After 18 h, cells were treated with fresh culture media with or without 100 μg/ml HA35 for 5 h and then challenged with 10 ng/ml LPS for another 60 min.
RNA isolation and quantitative real-time PCR (qRT-PCR). Total RNA was isolated using the Qiagen RNeasy mini kit, reverse transcribed and qRT-PCR amplification was performed. The relative amount of target mRNA was determined using the comparative threshold (Ct) method by normalizing target mRNA Ct values to those of 18S.

miRNA preparation and Next Generation Sequencing (NGS). Small RNA was isolated using miR-Neasy Mini Kit (Qiagen, Germantown, MD) and sequenced following the Small RNA Sample Preparation Protocol (Illumina, San Diego, USA). The library was prepared from 10 ng of total RNA per sample according to the manufacturers instructions (TruSeq Small RNA Kit, Illumina). Single-stranded cDNAs were created with SuperScriptII Reverse Transcriptase and double-stranded cDNAs generated by PCR using adapter specific primers. Purified libraries were quantified and qualified using the High Sensitivity DNA Kit on a 2100 Bioanalyzer (Agilent Technologies, Böblingen, Germany). Sequencing of the libraries was carried out at the Genomic Core Facility (Cleveland Clinic) utilizing HiSeq-2000 (Illumina). After sequencing, the data were obtained in Illumina FASTQ format. The data were analyzed using NGS small RNA sequence analysis software (version 2.5.1) using the rat build n4miRNA program (see Saikia, et al., 2017 for data analysis pipeline). MicroRNA array data have been deposited in NCBI’s Gene Expression Omnibus (accession number GSE95403).

Immunocytochemistry of Kupffer cells. Expression of cell surface receptors TLR2, TLR4, CD44, and RHAMM was detected by immunocytochemistry44. Briefly, after nucleofection with siRNA, Kupffer cells were plated on Lab-Tek chamber slides. After culture for 24 h, cells were fixed using 4% paraformaldehyde, washed with phosphate-buffered saline (PBS) and permeabilized with 0.1% Triton-X-100 for 10 minutes. Cells were then washed with PBS, quenched with glycine, blocked for 1 hour and incubated overnight with primary antibodies (see Supplemental Table 2 antibody sources) at 4 °C. Cells were then washed with PBS and incubated in the dark with secondary antibodies (Supplemental Table 2) for 1 hour at room temperature. Cells were again washed with PBS and mounted with a DAPI-containing mounting media. Images were acquired using Leica-confocal microscope using 40X objectives.

Western blot analysis. Primary cultures of Kupffer cells were treated with or without 100 µg/ml HA35 for 5 hrs and then challenged with LPS (10 ng/ml) for another 1 hr. Cells were then moved to ice, washed with 2 ml ice-cold PBS buffer and then lysed in RIPA buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 0.1% SDS) containing 1 mM sodium orthovanadate, 10 mM NaF, 10 mM sodium pyrophosphate, 10 mM β-glycerophosphate, 1 mM PMSF, 10 µg/ml aprotinin and protease inhibitor. Lysates were then centrifuged at 16,000 × g for 15 min at 4 °C. For Western blot analysis, 10 µg of cellular protein was separated on 10% SDS-PAGE gels and then transferred to PVDF membranes for immunoblotting. Membranes were blocked in BSA or non-fat milk and probed with specific antibodies against Tollip and HSC70 as a loading control. Western blot analysis was performed using enhanced chemiluminescence for signal detection. Signal intensities were quantified by densitometry using Image J software (NIH). To confirm equal loading of protein, blots were probed with antibodies specific for HSC70.

In situ hybridization of micro-RNA 291b in mouse liver using LNA probes. Making use of 5’, 3’ digoxigenin-tagged Locked nucleic acid (LNA) probe, obtained from Exiqon (Denmark), miR291b was visualized in paraffin-embedded livers from pair- or ethanol-fed mice45. Formalin-fixed paraffin-embedded liver sections were de-paraffinized, washed with DEPC-PBS and subjected to antigen retrieval using proteinase-K treatment (20 µg/ml) for 15 minutes at room temperature. Sections were then washed with DEPC-PBS and treated with 1-ethyl-3-(dimethylaminopropyl) carbodiimide-hydrochloride (EDC, Molecular Probes) for 90 minutes followed by sequential washing with 0.1 M Glycine/PBS for 10 minutes and DEPC-PBS, 3 times for 5 minutes each. Sections were then subjected to pre-hybridization for one hour at 40 °C followed by hybridization using 60 nM LNA-probe-containing hybridization buffer (30% formamide, 5x saline sodium citrate, 0.1% Tween-20, adjusted to pH 6.0 with 9.2 mM citric acid, 500 µg/ml yeast tRNA) for one hour at 45 °C in a humidified chamber. At the end of the hybridization, sections were sequentially treated with ice-cold SSC buffer (containing sodium chloride and citrate buffer), 3% H2O2 for 10 minutes, DEPC-PBS and in situ hybridization-blocking buffer from Roche (Mannheim, Germany Cat. No.11-096-176-001) for 1 hour. Sections were then exposed to anti-digoxigenin-HRP labeled antibody for 1 hour at room temperature. After the antibody incubation, sections were washed with TN-buffer followed by incubation with Tyramide signal amplification (TSA) reagent for 10 minutes in dark, washed three time with TN buffer and mounted using DAPI-containing mounting reagent. Images were acquired using 40X objective.

Statistical analysis. Values shown in all figures represent means ± SEM. Data was analyzed by Analysis of Variance using a general linear model and least square means test for comparisons between groups (SAS, Cary, NC). Normal distribution of the data was assessed using the Shapiro-Wilk test and data were log-transformed, if necessary, to obtain a normal distribution. Statistical difference between groups was determined at p < 0.05. Different alphabetical superscripts denote significant difference between groups.

References
1. Guirguis, J. et al. Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States. Alcohol Clin Exp Res 39, 2085–2094, https://doi.org/10.1111/acer.12887 (2015).
2. Nagy, L. E., Ding, W. X., Cresci, G., Saikia, P. & Shah, V. H. Linking Pathogenic Mechanisms of Alcoholic Liver Disease With Clinical Phenotypes. Gastroenterology 150, 1756–1768, https://doi.org/10.1053/j.gastro.2016.02.035 (2016).
3. Hartmann, P., Seebauer, C. T. & Schnabl, B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res 39, 763–775, https://doi.org/10.1111/acer.12704 (2015).
4. Wang, H. J., Gao, B., Zakhari, S. & Nagy, L. E. Inflammation in alcoholic liver disease. *Annu Rev Nutr* 32, 343–368, https://doi.org/10.1146/annurev-nutr-072610-145138 (2012).

5. Schmalb, B. & Brenner, D. A. Interactions between the intestinal microbiome and liver diseases. *Gastroenterology* 146, 1513–1524, https://doi.org/10.1053/j.gastro.2014.01.020 (2014).

6. Weigel, P. H., Hascall, V. C. & Tammi, M. Hyaluronan synthases. *J Biol Chem* 272, 13997–14000 (1997).

7. Petrey, A. C. & de la Motte, C. A. Hyaluronan, a crucial regulator of inflammation. *Front Immunol* 5, 101, https://doi.org/10.3389/fimmu.2014.00101 (2014).

8. Saikia, P. et al. miR181b-3p and its target importin alpha5 regulate TLR4 signaling in Kupffer cells and liver injury in mice in response to ethanol. *Hepatology*. https://doi.org/10.1002/hep.29144 (2017).

9. Didierlaurent, A. et al. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. *Mol Cell Biol* 26, 735–742, https://doi.org/10.1128/MCB.26.3.735-742.2006 (2006).

10. Burns, K. et al. Tollip, a new component of the IL-1R1 pathway, links IRAK to the IL-1 receptor. *Nat Cell Biol* 2, 346–351, https://doi.org/10.1038/s41598-017-15760-4 (2020).

11. Yoshio, K., Kakuma, S., Arao, M., Tsutsumi, Y. & Inoue, M. Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease. *Hepatology* 10, 769–773 (1989).

12. Milinkovic, M., Antin, J. H., Hergrueter, C. A., Underhill, C. B. & Sackstein, R. CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD. *Blood* 103, 740–742, https://doi.org/10.1182/blood-2003-05-1500 (2004).

13. Yang, B., Zhang, L. & Turley, E. A. Identification of two hyaluronan-binding domains in the hyaluronan receptor RHAMM. *J Biol Chem* 268, 8617–8623 (1993).

14. Yoo, K. et al. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. *J Biol Chem* 279, 17079–17084, https://doi.org/10.1074/jbc.M110.145870 (2011).

15. Warner, N. & Núñez, G. D88: a critical adaptor protein in innate immunity signal transduction. *J Immunol* 190, 3–4, https://doi.org/10.4049/jimmunol.1203103 (2013).

16. Liew, F. Y., Xu, D., Brint, E. K. & O’Neill, L. A. Negative regulation of toll-like receptor-mediated immune responses. *Nat Rev Immunol* 5, 446–458, https://doi.org/10.1038/nri1630 (2005).

17. Movita, D. et al. Kupffer cells express a unique combination of phenotypic and functional characteristics compared with splenic and peritoneal macrophages. *Journal of Leukocyte Biology* 92, 723–733, https://doi.org/10.1189/jlb.1111566 (2012).

18. Khachatourian, R. et al. SAKe treatment prevents the ethanol-induced epigenetic alterations of genes in the Toll-like receptor pathway. *Exp Mol Pathol* 94, 243–246, https://doi.org/10.1016/j.yexmp.2012.09.024 (2013).

19. Guo, J. et al. MiR-29b-3p Induces Apoptosis in Liver Cell Line NCTC1469 by Reducing the Level of RNA-binding Protein HuR. *Cellular Physiology and Biochemistry* 33, 810–822, https://doi.org/10.1159/000358654 (2014).

20. Guo, J. et al. Hepatic MiR-29b-3p Mediated Glucose Metabolism by Directly Targeting gp65 to Upregulate PTEN Expression. *Sci Rep* 7, 39899, https://doi.org/10.1038/srep39899 (2017).

21. Meng, X. et al. Liver MicroRNA-29b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5′-Monophosphate (AMP)-activated Protein Kinase alpha1. *J Biol Chem* 291, 10625–10634, https://doi.org/10.1074/jbc.M110.145870 (2011).

22. Warner, N. & Núñez, G. D88: a critical adaptor protein in innate immunity signal transduction. *J Immunol* 190, 3–4, https://doi.org/10.4049/jimmunol.1203103 (2013).

23. Hill, D. R. et al. Human milk hyaluronan enhances innate defense of the intestinal epithelium. *J Biol Chem* 288, 29909–29910, https://doi.org/10.1074/jbc.M112.368629 (2013).

24. Kim, Y. et al. Hyaluronan 35kDa treatment protects mice from Citrobacter rodentium infection and induces epithelial tight junction protein ZO-1 in vivo. *Matrix Biol.* https://doi.org/10.1016/j.matbio.2016.11.001 (2016).

25. Stern, R. Hyaluronan catabolism: a new metabolic pathway. *Eur J Cell Biol* 83, 317–325, https://doi.org/10.1078/0171-9335-00392 (2004).

26. Cowman, J. M., Reed, R. K. & Laurent, T. C. Increased plasma concentrations of hyaluronan after major thermal injury in the rat. *Circ Shock* 37, 159–163 (1992).

27. Nairn, H., Reed, R. K. & Lauret, T. C. Increased plasma concentrations of hyaluronan after major thermal injury in the rat. *Circ Shock* 37, 159–163 (1992).

28. Pare, A. et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. *Hepatology* 24, 1399–1403, https://doi.org/10.1002/hep.510240615 (1996).

29. Sowa, J. P. et al. Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling. *PLoS One* 9, e101444, https://doi.org/10.1371/journal.pone.0101444 (2014).

30. Johnson, P. & Ruffell, B. CD44 and its role in inflammation and inflammatory diseases. *Inflamm Allergy Drug Targets* 8, 208–220 (2009).

31. Wen, Y., Jeong, S., Chia, Q. & Kong, X. Role of Osteopontin in Liver Diseases. *Int J Biol Sci* 12, 1121–1128, https://doi.org/10.7150/ijbs.16445 (2016).

32. Ge, X., Lu, Y., Leung, T. M., Sorenson, S. E. & Nieto, N. Milk osteopontin, a nutritional approach to prevent alcohol-induced liver injury. *Am J Physiol Gastrointest Liver Physiol* 304, C929–C939, https://doi.org/10.1152/ajpgi.00014.2013 (2013).

33. Thakur, V., McMullen, M. R., Pritchard, M. T. & Nagy, L. E. Regulation of macrophage activation in alcoholic liver disease. *J Gastroenterol Hepatol* 22(Suppl 1), S53–S56, https://doi.org/10.1111/j.1440-1746.2006.04650.x (2007).
43. Mandal, P. et al. Adiponectin and heme oxygenase-1 suppress TLR4/MyD88-independent signaling in rat Kupffer cells and in mice after chronic ethanol exposure. *J Immunol* **185**, 4928–4937, https://doi.org/10.4049/jimmunol.1002060 (2010).
44. McMullen, M. R., Cocuzzi, E., Hatzoglou, M. & Nagy, L. E. Chronic ethanol exposure increases the binding of HuR to the TNFalpha 3′-untranslated region in macrophages. *J Biol Chem* **278**, 38333–38341, https://doi.org/10.1074/jbc.M304566200 (2003).
45. Dutta, R. et al. Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. *Ann Neurol* **73**, 637–645, https://doi.org/10.1002/ana.23860 (2013).

Acknowledgements

This work was supported in part by NIH grants P50AA024333, U01AA021890 and R21AA024387 (LEN); Programs of Excellence in Glycosciences Grant HL107147 (CdlM) and F31 AA024017 (DB). This work was supported in part by the Case Western Reserve University/Cleveland Clinic CTSA UL1RR024989 and utilized the Leica SP5 confocal/multi-photon microscope and Next Generation Sequencer that were purchased with partial funding from National Institutes of Health SIG grant 1S10RR026820 and S10OD018058, respectively.

Author Contributions

P.S., S.R., K.A.P., M.R.M., R.L.M. conducted experiments and collected data. P.S., D.B., C.d.l.M., L.E.N.: experimental design and data analysis. A.J.M., P.G.: provided A.H. patient samples. P.S., L.E.N.: wrote manuscript. L.E.N., C.d.l.M.: provided funding All authors reviewed the final manuscript.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-15760-4.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017